577 related articles for article (PubMed ID: 25574858)
1. Plasma soluble urokinase-type plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease.
Mekonnen G; Corban MT; Hung OY; Eshtehardi P; Eapen DJ; Al-Kassem H; Rasoul-Arzrumly E; Gogas BD; McDaniel MC; Pielak T; Thorball CW; Sperling L; Quyyumi AA; Samady H
Atherosclerosis; 2015 Mar; 239(1):55-60. PubMed ID: 25574858
[TBL] [Abstract][Full Text] [Related]
2. Soluble urokinase plasminogen activator receptor is in contrast to high-sensitive C-reactive-protein associated with coronary artery calcifications in healthy middle-aged subjects.
Sørensen MH; Gerke O; Eugen-Olsen J; Munkholm H; Lambrechtsen J; Sand NP; Mickley H; Rasmussen LM; Olsen MH; Diederichsen A
Atherosclerosis; 2014 Nov; 237(1):60-6. PubMed ID: 25222341
[TBL] [Abstract][Full Text] [Related]
3. Predicting Mortality in African Americans With Type 2 Diabetes Mellitus: Soluble Urokinase Plasminogen Activator Receptor, Coronary Artery Calcium, and High-Sensitivity C-Reactive Protein.
Hayek SS; Divers J; Raad M; Xu J; Bowden DW; Tracy M; Reiser J; Freedman BI
J Am Heart Assoc; 2018 May; 7(9):. PubMed ID: 29716888
[TBL] [Abstract][Full Text] [Related]
4. Soluble urokinase plasminogen activator receptor level is an independent predictor of the presence and severity of coronary artery disease and of future adverse events.
Eapen DJ; Manocha P; Ghasemzadeh N; Patel RS; Al Kassem H; Hammadah M; Veledar E; Le NA; Pielak T; Thorball CW; Velegraki A; Kremastinos DT; Lerakis S; Sperling L; Quyyumi AA
J Am Heart Assoc; 2014 Oct; 3(5):e001118. PubMed ID: 25341887
[TBL] [Abstract][Full Text] [Related]
5. Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes.
Samman Tahhan A; Hayek SS; Sandesara P; Hajjari J; Hammadah M; O'Neal WT; Kelli HM; Alkhoder A; Ghasemzadeh N; Ko YA; Aida H; Gafeer MM; Abdelhadi N; Mohammed KH; Patel K; Arya S; Reiser J; Vaccarino V; Sperling L; Quyyumi A
Atherosclerosis; 2017 Sep; 264():108-114. PubMed ID: 28728756
[TBL] [Abstract][Full Text] [Related]
6. Cardiac and proinflammatory markers predict prognosis in cirrhosis.
Wiese S; Mortensen C; Gøtze JP; Christensen E; Andersen O; Bendtsen F; Møller S
Liver Int; 2014 Jul; 34(6):e19-30. PubMed ID: 24313898
[TBL] [Abstract][Full Text] [Related]
7. Cardio-Renal Biomarker Soluble Urokinase-Type Plasminogen Activator Receptor Is Associated With Cardiovascular Death and Myocardial Infarction in Patients With Coronary Artery Disease Independent of Troponin, C-Reactive Protein, and Renal Function.
Nikorowitsch J; Borchardt T; Appelbaum S; Ojeda F; Lackner KJ; Schnabel RB; Blankenberg S; Zeller T; Karakas M
J Am Heart Assoc; 2020 Apr; 9(8):e015452. PubMed ID: 32299288
[TBL] [Abstract][Full Text] [Related]
8. Soluble Urokinase-Type Plasminogen Activator Receptor and High-Sensitivity Troponin Levels Predict Outcomes in Nonobstructive Coronary Artery Disease.
Al-Badri A; Tahhan AS; Sabbak N; Alkhoder A; Liu C; Ko YA; Vaccarino V; Martini A; Sidoti A; Goodwin C; Ghazzal B; Beshiri A; Murtagh G; Mehta PK; Quyyumi AA
J Am Heart Assoc; 2020 Apr; 9(8):e015515. PubMed ID: 32301366
[TBL] [Abstract][Full Text] [Related]
9. Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmö Diet and Cancer Study.
Persson M; Engström G; Björkbacka H; Hedblad B
Atherosclerosis; 2012 Feb; 220(2):502-5. PubMed ID: 22119508
[TBL] [Abstract][Full Text] [Related]
10. Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events.
Sehestedt T; Lyngbæk S; Eugen-Olsen J; Jeppesen J; Andersen O; Hansen TW; Linneberg A; Jørgensen T; Haugaard SB; Olsen MH
Atherosclerosis; 2011 May; 216(1):237-43. PubMed ID: 21354571
[TBL] [Abstract][Full Text] [Related]
11. Soluble urokinase Plasminogen Activator Receptor (suPAR) mediates the effect of a lower education level on adverse outcomes in patients with coronary artery disease.
Füller D; Liu C; Ko YA; Alkhoder AA; Desai SR; Almuwaqqat Z; Patel SA; Ejaz K; Kauser T; Martini MA; Alvi Z; Mehta PK; Sperling LS; Quyyumi AA
Eur J Prev Cardiol; 2024 Mar; 31(5):521-528. PubMed ID: 37788634
[TBL] [Abstract][Full Text] [Related]
12. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis.
Zimmermann HW; Koch A; Seidler S; Trautwein C; Tacke F
Liver Int; 2012 Mar; 32(3):500-9. PubMed ID: 22098627
[TBL] [Abstract][Full Text] [Related]
13. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.
Enocsson H; Wetterö J; Skogh T; Sjöwall C
Transl Res; 2013 Nov; 162(5):287-96. PubMed ID: 23916811
[TBL] [Abstract][Full Text] [Related]
14. Coronary microvascular dysfunction is associated with higher frequency of thin-cap fibroatheroma.
Dhawan SS; Corban MT; Nanjundappa RA; Eshtehardi P; McDaniel MC; Kwarteng CA; Samady H
Atherosclerosis; 2012 Aug; 223(2):384-8. PubMed ID: 22766333
[TBL] [Abstract][Full Text] [Related]
15. Cadmium exposure is associated with soluble urokinase plasminogen activator receptor, a circulating marker of inflammation and future cardiovascular disease.
Fagerberg B; Borné Y; Barregard L; Sallsten G; Forsgard N; Hedblad B; Persson M; Engström G
Environ Res; 2017 Jan; 152():185-191. PubMed ID: 27792942
[TBL] [Abstract][Full Text] [Related]
16. SuPAR is associated with death and adverse cardiovascular outcomes in patients with suspected coronary artery disease.
Hodges G; Lyngbæk S; Selmer C; Ahlehoff O; Theilade S; Sehestedt TB; Abildgaard U; Eugen-Olsen J; Galløe AM; Hansen PR; Jeppesen JL; Bang CN
Scand Cardiovasc J; 2020 Dec; 54(6):339-345. PubMed ID: 32400206
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of suPAR and hs-CRP on cardiovascular disease.
Diederichsen MZ; Diederichsen SZ; Mickley H; Steffensen FH; Lambrechtsen J; Sand NPR; Christensen KL; Olsen MH; Diederichsen A; Grønhøj MH
Atherosclerosis; 2018 Apr; 271():245-251. PubMed ID: 29402404
[TBL] [Abstract][Full Text] [Related]
18. Soluble urokinase plasminogen activator receptor is compartmentally regulated in decompensated cirrhosis and indicates immune activation and short-term mortality.
Zimmermann HW; Reuken PA; Koch A; Bartneck M; Adams DH; Trautwein C; Stallmach A; Tacke F; Bruns T
J Intern Med; 2013 Jul; 274(1):86-100. PubMed ID: 23432143
[TBL] [Abstract][Full Text] [Related]
19. Significantly increased concentration of soluble urokinase-type plasminogen activator receptor in the blood of patients with pelvic inflammatory disease.
Yeh YH; Wang PH; Lin LY; Tee YT; Chou MC; Yang SF; Tsai HT
Clin Chim Acta; 2013 Jan; 415():138-44. PubMed ID: 23117033
[TBL] [Abstract][Full Text] [Related]
20. Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetes.
Theilade S; Lyngbaek S; Hansen TW; Eugen-Olsen J; Fenger M; Rossing P; Jeppesen JL
J Intern Med; 2015 Mar; 277(3):362-371. PubMed ID: 24830873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
